Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Director Douglas L. Braunstein sold 159,223 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $56.81, for a total transaction of $9,045,458.63. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
EGRX stock opened at $54.79 on Thursday. The company has a debt-to-equity ratio of 0.21, a current ratio of 4.12 and a quick ratio of 3.89. Eagle Pharmaceuticals Inc has a one year low of $36.03 and a one year high of $85.66. The company has a market capitalization of $774.06 million, a price-to-earnings ratio of 26.22 and a beta of 1.67.
Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $1.01 EPS for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.28. Eagle Pharmaceuticals had a net margin of 17.67% and a return on equity of 21.38%. The business had revenue of $49.80 million during the quarter, compared to analysts’ expectations of $47.03 million. During the same quarter in the previous year, the company earned $0.55 EPS. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. As a group, equities research analysts forecast that Eagle Pharmaceuticals Inc will post 1.75 earnings per share for the current fiscal year.
A number of equities analysts have commented on EGRX shares. Royal Bank of Canada set a $66.00 price target on shares of Eagle Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, March 1st. Zacks Investment Research raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a research note on Friday, February 1st. BidaskClub raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, March 5th. ValuEngine raised shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, March 1st. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $58.00 price target on shares of Eagle Pharmaceuticals in a research note on Thursday, February 28th. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Eagle Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $65.17.
ILLEGAL ACTIVITY WARNING: “Insider Selling: Eagle Pharmaceuticals Inc (EGRX) Director Sells 159,223 Shares of Stock” was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.baseballdailydigest.com/news/2019/05/16/insider-selling-eagle-pharmaceuticals-inc-egrx-director-sells-159223-shares-of-stock.html.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.
Further Reading: Are all No-Load Funds Equal?
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.